We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

117 hedge funds and large institutions have $179M invested in Entrada Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 28

63% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 16

37% more call options, than puts

Call options by funds: $111K | Put options by funds: $81K

9% more funds holding

Funds holding: 107 → 117 (+10)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3.09% less ownership

Funds ownership: 82.53% → 79.44% (-3.1%)

15% less capital invested

Capital invested by funds: $210M → $179M (-$31.7M)

Holders
117
Holders Change
+10
Holders Change %
+9.35%
% of All Funds
1.54%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
26
Increased
49
Reduced
28
Closed
16
Calls
$111K
Puts
$81K
Net Calls
+$30K
Net Calls Change
-$114K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$3.9M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.48M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.38M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.26M
5
Jane Street
Jane Street
New York
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12.9M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$10.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.72M
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$685K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$622K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.07M -$108K -18,434 -9%
BNP Paribas Financial Markets
27
BNP Paribas Financial Markets
France
$860K +$849K +145,167 +4,767%
JP Morgan Chase
28
JP Morgan Chase
New York
$776K +$689K +117,844 +735%
AG
29
Algert Global
California
$753K +$759K +129,812 New
Bank of America
30
Bank of America
North Carolina
$733K +$526K +89,975 +247%
TI
31
Trexquant Investment
Connecticut
$713K +$657K +112,288 +1,062%
CSS
32
Cubist Systematic Strategies
Connecticut
$712K +$718K +122,676 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$614K +$45.5K +7,778 +8%
MCM
34
Moore Capital Management
New York
$609K – – –
Walleye Capital
35
Walleye Capital
New York
$561K +$464K +79,272 +455%
Two Sigma Investments
36
Two Sigma Investments
New York
$541K +$545K +93,194 New
XT
37
XTX Topco
Cayman Islands
$540K +$545K +93,079 New
American Century Companies
38
American Century Companies
Missouri
$437K +$1.75K +300 +0.4%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$415K +$419K +71,548 New
Ameriprise
40
Ameriprise
Minnesota
$406K +$146K +24,980 +56%
Barclays
41
Barclays
United Kingdom
$352K +$14.9K +2,548 +4%
QCM
42
Quantinno Capital Management
New York
$338K +$232K +39,607 +213%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$330K +$6.48K +1,108 +2%
N
44
Nuveen
North Carolina
$327K – – –
GCP
45
GSA Capital Partners
United Kingdom
$325K +$327K +55,960 New
Los Angeles Capital Management
46
Los Angeles Capital Management
California
$302K +$43.6K +7,447 +17%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$299K +$301K +51,500 New
NFGH
48
Nan Fung Group Holdings
Hong Kong
$285K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$245K +$133K +22,797 +118%
GLA
50
Great Lakes Advisors
Illinois
$238K +$240K +41,029 New
1
2
3 4 5

TRDA Hedge Fund Activity: Q3 2025 in Review

117 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2025, worth a combined $179M — down 15% from $210M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new TRDA positions and 16 closed out — a net gain of 10 holders — while 49 added to existing stakes and 28 trimmed.

The largest buyer was Millennium Management, adding an estimated $3.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.9M.

  • 117 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2025, up from 107 in Q2 2025.
  • Funds reported $179M of Entrada Therapeutics stock for Q3 2025, down 15% quarter-over-quarter.
  • 26 funds opened new Entrada Therapeutics positions in Q3 2025 and 16 closed out, a net change of +10 holders.
  • The largest Entrada Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $3.9M added.
  • The largest Entrada Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $12.9M sold.

Based on aggregated 13F filings for Q3 2025.